Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies - Hochberg, M.C. (Osteoarthritis and cartilage, 2015)
Keywords: Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal, Humanized - adverse effects; Fulranumab; Humans; Joint Diseases - chemically induced; Monoclonal antibodies to nerve growth factor; Nerve Growth Factor - antagonists & inhibitors; Osteonecrosis; Osteonecrosis - chemically induced; Randomized Controlled Trials as Topic; Rapidly progressive osteoarthritis; Rheumatology; Tanezumab; Monoclonal antibodies to nerve growth factor; Fulranumab; Rapidly progressive osteoarthritis; Osteonecrosis; Tanezumab